ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding Div RTS (OP:RHHVF)

455.00 -5.70 (-1.24%)

Streaming Delayed Price Updated: 3:57 PM EDT, Aug 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	145
Open	467.14
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	460.70
Today's Range	452.18 - 467.14
52wk Range	300.15 - 490.33
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗

June 11, 2026

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

Via MarketBeat

Sarepta Therapeutics Inc.: Why it's a rising gene therapy star

January 23, 2024

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.

Via MarketBeat

Performance

YTD	+12.7%	+12.7%
1 Month	+13.1%	+13.1%
3 Month	+10.8%	+10.8%
6 Month	+0.1%	+0.1%
1 Year	+51.2%	+51.2%

More News

Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M ↗

January 02, 2024

Via Benzinga

Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗

December 11, 2023

Via Benzinga

Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗

December 05, 2023

Via Benzinga

Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs ↗

December 04, 2023

Via Benzinga

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗

October 31, 2023

Via Benzinga

Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗

October 19, 2023

Via Benzinga

What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗

October 17, 2023

Via Benzinga

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Via Benzinga

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗

September 21, 2023

Via Benzinga

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗

September 07, 2023

Via Benzinga

Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer ↗

September 01, 2023

Via Benzinga

Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time ↗

August 30, 2023

Via Benzinga

Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗

August 23, 2023

Via Benzinga

Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study ↗

August 23, 2023

Via Benzinga

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Via Benzinga

Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗

July 28, 2023

Via Benzinga

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗

July 26, 2023

Via Benzinga

Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗

July 24, 2023

Via Benzinga

Nvidia Invested $50 million into This AI Drug Discovery Biotech

July 17, 2023

Via MarketBeat

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗

July 14, 2023

Via Benzinga

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗

July 13, 2023

Via Benzinga

Agilent Technologies Stock: Ready to Rise off the Floor

June 21, 2023

Via MarketBeat

Frequently Asked Questions

Is Roche Holding Div RTS publicly traded?

Yes, Roche Holding Div RTS is publicly traded.

What exchange does Roche Holding Div RTS trade on?

Roche Holding Div RTS trades on the OTC Traded

What is the ticker symbol for Roche Holding Div RTS?

The ticker symbol for Roche Holding Div RTS is RHHVF on the OTC Traded

What is the current price of Roche Holding Div RTS?

The current price of Roche Holding Div RTS is 455.00

When was Roche Holding Div RTS last traded?

The last trade of Roche Holding Div RTS was at 08/10/26 03:57 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.